|
|
|
| Effect of Compound Chaijin Jieyu Tablets in the treatment of depression and its influence on serum inflammatory factors and neurotransmitters |
| ZHUO Dan1 WANG Yuhong1,2 YU Jingbo1,2 ZHAO Hongqing3 LI Zirong1 YAN Xiaoyuan2,3 HE Haixia3 YAO Xinyan3 |
1.Hu’nan University of Chinese Medicine, Hu’nan Province, Changsha 410208, China;
2.the National Key Laboratory Breeding Base of Hu’nan Province Traditional Chinese Medicine Powder and Innovative Medicine Ministry, Hu’nan Province, Changsha 410208, China;
3.the First Affiliated Hospital of Hu’nan University of Chinese Medicine, Hu’nan Province, Changsha 410007, China |
|
|
|
Abstract Objective To explore the effect of Compound Chaijin Jieyu Tablets in treating depression and its influence on serum inflammatory factors and monoamine neurotransmitters. Methods A total of 80 patients with depression admitted to the Department of Neurology, the First Affiliated Hospital of Hu’nan University of Chinese Medicine from May 2018 to December 2019 were selected. All observed cases were divided into observation group and control group according to the random number table method, with 40 cases in each group. The course of treatment was eight weeks. The observation group was treated with self-prepared Compound Chaijin Jieyu Tablets, and the control group was treated with Western medicine Hydrochloride Sertraline Tablets. The clinical efficacy and traditional Chinese medicine (TCM) syndromes efficacy were compared between the two groups after four and eight weeks of treatment. The levels of serum monoamine neurotransmitters (5-hydroxytryptamine, norepinephrine, dopamine) and inflammatory factors (tumor necrosis factor-α, interleukin-6, interleukin-2) were compared between the two groups after eight weeks of treatment. The safety of the two groups was observed. Results During the treatment, two patients in the control group and three patients in the observation group fell off. After four weeks of treatment, there was no significant difference in clinical efficacy and TCM syndrome efficacy between the two groups (P ＞ 0.05). After eight weeks of treatment, there was no statistically significant difference in clinical efficacy between the two groups (P ＞ 0.05), but the total effective rate of TCM syndromes in the observation group was higher than that in the control group, with statistically significant difference (P ＜ 0.05). After eight weeks of treatment, the levels of monoamine neurotransmitters were higher than those before the treatment, and the levels of inflammatory factors were lower than those before the treatment, with statistical significant differences (all P ＜ 0.05). But there was no statistical significance in serum levels of inflammatory factors and neurotransmitters between groups (P ＞ 0.05). The patients’ liver and kidney function, myocardial enzymes, three routine tests, and electrocardiogram examination before and after treatment were not found any obvious abnormal changes. Conclusion The Compound Chaijin Jieyu Tablet has a positive effect on the treatment of depression with liver depression and spleen deficiency, and has high safety, which is suitable for clinical application.
|
|
|
|
|
|
[1] 郝伟，陆林.精神病学[M].北京：人民卫生出版社，2018：105.
[2] 朱文娴，袁国桢.中西医结合治疗抑郁症的临床研究现状[J].现代中西医结合杂志，2019，28（27）：3075-3078.
[3] 李德智.抑郁症中医证候及证候要素分布特点的文献研究[J].光明中医，2018，33（19）：2781-2783.
[4] 中华医学会精神病学分会.中国精神障碍分类与诊断标准第三版（精神障碍分类）[J].中华精神科杂志，2001，34（3）：184-188.
[5] 张伯礼，吴勉华.中医内科学[M].北京：中国中医药出版社，2017：289-295.
[6] 卓丹，贺海霞，李姿蓉，等.复方柴金解郁片治疗肝郁脾虚型抑郁症的临床观察[J].中医药导报，2020，26（16）：72-77.
[7] 卢瑾，李凌江，许秀峰.中国抑郁障碍防治指南（第二版）解读：评估与诊断[J].中华精神科杂志，2017，50（3）：169-171.
[8] 郑筱萸.中药新药临床研究指导原则（试行）[M].北京：中国医药科技出版社，2002：366.
[9] 魏晓楠，郝铁成.中药提取新技术研究进展[J].中国野生植物资源，2020，39（9）：47-50.
[10] 韩远山，王宇红，杜青，等.复方柴金解郁片对嗅球损毁抑郁模型大鼠行为学及海马MAO和5-HT—（1A）受体的影响[J].时珍国医国药，2017，28（7）：1580-1582.
[11] 韩远山，蔺晓源，易刚强，等.复方柴金解郁片对慢性应激抑郁大鼠HPA轴及海马单胺神经递质的影响[J].湖南中医药大学学报，2017，37（3）：240-244.
[12] 韩远山，蔺晓源，邵乐，等.复方柴金解郁片抗抑郁作用的实验研究[J].湖南中医药大学学报，2017，37（1）：18-21.
[13] 黄良峰，陈洋洋，赵炳功，等.抑郁症的成因及其新药治疗研究进展[J].现代生物医学进展，2018，18（1）：180-185.
[14] 冯睿，张佳莉，赫明超，等.中药及其活性成分防治抑郁症的药理靶点与临床应用[J].中国临床药理学与治疗学，2020，25（4）：467-474.
[15] 尹冬青，田金洲，时晶，等.15196例抑郁症中医证候及证候要素特点的文献研究[J].中华中医药学刊，2013， 31（2）：279-282.
[16] 李德智.抑郁症中医证候及证候要素分布特点的文献研究[J].光明中医，2018，33（19）：2781-2783.
[17] 傅松年，阿不都克热木·阿不都热合曼，罗福祥，等.贯叶金丝桃提取物对小鼠行为学的影响[J].中国医药导报，2019，16（21）：17-20.
[18] 安继东，郭旭彤，陈分乔，等.近5年中药治疗抑郁症及其作用机制研究进展[J].辽宁中医药大学学报，2020， 22（8）：139-142.
[19] 张文渊，李焕德.抑郁症中枢神经递质及治疗研究进展[J].中国临床药理学杂志，2010，26（7）：540-544.
[20] 谭余庆，谷春华，杨庆，等.解郁除烦胶囊对抑郁症模型小鼠行为学及脑内单胺类神经递质的影响[J].国际中医中药杂志，2016，38（10）：914-917.
[21] 慕磊，孙建绪.抑郁症发病机制与抗抑郁药物作用靶标[J].国际药学研究杂志，2015，42（4）：463-466.
[22] 李红，毛叶萌.抑郁症发病机制的免疫学研究进展[J].中国免疫学杂志，2016，32（5）：760-763.
[23] 许二平，苗明三，尚立芝.基于抑郁症细胞因子、神经-内分泌发病机制的中医药治疗新进展[J].河南中医，2017， 37（2）：233-237.
[24] 邓朔，张鸿燕.抑郁症发病机制的神经免疫相关靶点研究现状[J].中国临床药理学杂志，2017，33（3）：280-283.
[25] 王均辉，孙峰波，秦绿叶，等.异常活化的小胶质细胞的特征与功能[J].生理科学进展，2008，39（1）：41-44.
[26] 王东林，林文娟.细胞因子与抑郁症发病机制研究进展[J].中国神经精神疾病杂志，2007（9）：572-574. |
|
|
|
